4SC AG’s Stage IIb research evaluates efficacy of vidofludimus in RA patients 4SC AG, a drug discovery and development company centered on autoimmune and cancer indications, reported that it has completed enrolment of its COMPONENT Phase IIb research with vidofludimus today, an oral inhibitor of IL-17 release, in rheumatoid arthritis individuals. Data from the trial are anticipated to be announced in Q2 2011 www.sildenafilini.com . COMPONENT is a randomised, double-blind, placebo-controlled, multi-centre, international Phase IIb study analyzing the efficacy of vidofludimus in RA with methotrexate, compared to methotrexate alone.
Therefore, 4SC-205 gets the potential to generate a therapeutic impact analogous to other anti-mitotic drugs however avoiding peripheral nerve harm commonly seen after taxane chemotherapy. In preclinical research 4SC-205 shown encouraging anti-tumour activity in a number of in vitro and in vivo models. Dr Bernd Hentsch, Chief Development Officer of 4SC commented, ‘With the commencement of this trial, we now have prolonged our oncology pipeline to add a third compound. This anti-mitotic agent, predicated on earlier preclinical results, could be positioned in a variety of cancer indications. Over the last twelve months 4SC has established a strong, medical stage oncology investigating multiple, innovative approaches for the treatment of both haematological and solid cancers.’..